triple glp 1 agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism What GLP‑3 Really Is: Retatrutide

Experts suggest a quick "rebound" effect in appetite and metabolism after stopping the drug, compounded by the stress of pregnancy

At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk

In the cohort analyses patients who initiated GLP-1 RAs did not differ in the hazard ratio (HR) for suicide or suicide attempts from SGLT-2 inhibitor users (HR: 0.93

Tirzepatide), metabolic outcomes, and next-gen weight loss benefits

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.